Exicure, Inc. Common Stock (XCUR)
Exicure, Inc. (XCUR) is a biotechnology company focused on developing innovative nucleic acid therapeutics using its proprietary spherical nucleic acid (SNA) technology. The company aims to address challenging genetic and inflammatory diseases with its platform, which facilitates targeted gene regulation and modulation. Based in Chicago, Exicure leverages its scientific expertise to advance therapies in areas such as oncology, dermatology, and immunology.
Company News
Biotechnology company Exicure reported no revenue in Q2 2025, a widened net loss of $2.6 million, and a critical need for additional financing after acquiring GPCR Therapeutics USA Inc. The company is pivoting to focus on stem cell mobilization therapies for blood disorders.
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. FMC posted adjusted earnings of $1.07 per share, missing market estimates of $1.08 per share. The company’s quarterly sales came in at $1.15 billion versus expectations of $1.25 billion. FMC shar...
Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -68.75% and 559.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?